Supernus Pharmaceuticals reported $31.99M in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Abbott ABT:US $ 2985M 750M
Aerie Pharmaceuticals AERI:US $ -16.59M 15.45M
Aurora Cannabis Inc ACB:CN -88561000 17.03M
Bristol Myers Squibb BMY:US $ 5780M 8M
Canopy Growth Corp WEED:CN C$ -92586000 186.28M
Cara Therapeutics CARA:US $ -4409000 23.44M
Corcept Therapeutics CORT:US $ 31.55M 4.49M
Eisai 4523:JP Y 17237M 28829M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Horizon Pharma HZNP:US $ 244.43M 47.12M
JAZZ PHA JAZZ:US $ 282.55M 15.29M
Lannett LCI:US $ -12.48M 3.96M
Marinus Pharmaceuticals MRNS:US $ -36.67M 20.05M
Pacira Pharmaceuticals PCRX:US $ 34.04M 7.72M
Perrigo Ordinary Shares PRGO:US $ 86.1M 6.5M
Pfizer PFE:US $ 12921M 1739M
Revance Therapeutics RVNC:US $ -52.39M 4.45M
Supernus Pharmaceuticals SUPN:US $ 31.99M 8.66M
Teva Pharmaceutical Industries TEVA:US $ 1092M 20M
United Therapeutics UTHR:US $ 214.5M 86M
Xeris Pharmaceuticals Inc XERS:US $ -15854000 188K